Covid19 Clinical Trial
— MEDyMAPOfficial title:
Evaluation of the Response of COVID-19 Spread With a Spatiotemporal Analysis in a Tertiary Hospital
NCT number | NCT04581096 |
Other study ID # | COVID19-MAPA |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2, 2020 |
Est. completion date | June 15, 2021 |
Verified date | November 2021 |
Source | Hospital General Universitario de Valencia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. how infected people have moved and whom they came in contact with, which is hardly ever available. The researchers propose a novel approach to the study of the propagation of COVID-19, in which a proxy of this information is derived at macroscopic scales. This will be based on two ingredients: the spatiotemporal study in shiny with mathematical models with aggregated or non aggregated data and the reconstruction of functional networks of spreading patterns, and the development of a supporting software.
Status | Completed |
Enrollment | 2646 |
Est. completion date | June 15, 2021 |
Est. primary completion date | February 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - positive test (PCR or serology) for SARS-CoV-2 - outpatient follow-up Exclusion Criteria: - hospitalisation in ward or ICU |
Country | Name | City | State |
---|---|---|---|
Spain | CHGUV | Valencia | |
Spain | CHGUV | Valencia |
Lead Sponsor | Collaborator |
---|---|
Hospital General Universitario de Valencia | University of Valencia |
Spain,
Briz-Redón Á, Iftimi A, Correcher JF, De Andrés J, Lozano M, Romero-García C. A comparison of multiple neighborhood matrix specifications for spatio-temporal model fitting: a case study on COVID-19 data. Stoch Environ Res Risk Assess. 2021 Aug 18:1-12. doi: 10.1007/s00477-021-02077-y. [Epub ahead of print] — View Citation
Romero García C, Iftimi A, Briz-Redón Á, Zanin M, Otero M, Ballester M, de Andrés J, Landoni G, de Las Marinas D, Catalá Bauset JC, Mandingorra J, Conca J, Correcher J, Ferrer C, Lozano M. Trends in Incidence and Transmission Patterns of COVID-19 in Valencia, Spain. JAMA Netw Open. 2021 Jun 1;4(6):e2113818. doi: 10.1001/jamanetworkopen.2021.13818. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | spatiotemporal spread | spatiotemporal spread of COVID-19 patient in our hospital | February 1, 2020 to September 30, 2020 | |
Secondary | classification score | risk classification score of each patients with clinical and analytical variables | February 1, 2020 to September 30, 2020 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |